On October 6, 2026, leading nuclear medicine and uro-oncology consortiums published updated clinical consensus guidelines endorsing Pluvicto® (Lutetium Lu 177 vipivotide tetraxetan injection) by Novartis as the premier targeted radioligand therapy for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Combining molecular precision targeting with localized beta-radiation cytotoxicity, Pluvicto delivers prolonged radiographic progression-free survival and overall survival in heavily pretreated patient populations.

Through Onco Medicine, certified genuine Novartis supplies of Pluvicto 1000 MBq/mL Solution for Injection are coordinated for qualified nuclear medicine centers, specialty oncology hospitals, and named patients globally via time-critical radioisotope transport and full regulatory import clearances.

Mechanism of Action: PSMA-Targeted Beta Radiation

Pluvicto embodies the precision theranostics model in contemporary uro-oncology:

• High-Affinity Ligand Binding: Vipivotide tetraxetan binds with nanomolar affinity to the extracellular domain of PSMA, a transmembrane carboxypeptidase overexpressed on >80% of metastatic prostate cancer cells.
• Internalization & DNA Damage: Upon binding, the ligand-receptor complex is rapidly internalized into tumor cells via endocytosis. The conjugated beta-emitting radioisotope Lutetium-177 (177Lu) emits ionizing radiation with a maximal tissue penetration of approximately 2 mm, causing lethal double-strand DNA breaks while sparing distant healthy tissues.
• Physical Characteristics of 177Lu: Decays with a physical half-life of 6.647 days, emitting medium-energy beta minus particles (0.498 MeV max) and low-energy gamma photons that permit post-infusion SPECT/CT imaging for real-time biodistribution verification.

The Landmark VISION Phase 3 Evidence

Clinical efficacy was conclusively proven in the international Phase 3 VISION trial:

• Survival Advantage: Treatment with Pluvicto plus standard of care demonstrated a statistically significant 38% reduction in the risk of death (hazard ratio 0.62) compared to standard of care alone in patients previously treated with androgen receptor pathway inhibitors (ARPI) and taxane-based chemotherapy.
• Radiographic PFS: Significantly extended median radiographic progression-free survival (8.7 months vs. 3.4 months), with profound PSA50 response rates exceeding 46%.
• Theranostic Stratification: Eligibility is established using gallium-68 PSMA-11 or fluorine-18 DCFPyL PET/CT imaging, ensuring that only patients with verified PSMA-avid lesions receive targeted radiation therapy.

Administration Protocols & Radiation Safety Safeguards

Radiopharmaceutical delivery requires rigorous adherence to radiation hygiene:

• Dosing Regimen: Administered intravenously at a dose of 7.4 GBq (200 mCi) once every 6 weeks for up to 6 cycles, contingent upon adequate bone marrow reserve and absence of dose-limiting toxicities.
• Renal & Salivary Protection: Generous pre- and post-infusion hydration and application of cold packs to salivary glands (which exhibit physiological PSMA expression) reduce xerostomia and radiation-induced nephrotoxicity.
• Hematologic Surveillance: Complete blood counts and renal function panels (serum creatinine, eGFR) must be verified prior to every cycle; cytopenias (anemia, thrombocytopenia, neutropenia) are managed with cycle delays or dose reductions to 5.55 GBq (150 mCi).

Time-Sensitive Global Access via Onco Medicine

Because Lutetium-177 undergoes continuous radioactive decay, international procurement demands flawless logistics:

• Calibrated Batch Scheduling: Precise radioisotope calibration synchronized with destination clinic infusion slots, ensuring exact administered radioactivity upon patient arrival.
• Nuclear Regulatory Compliance: Coordinated under US FDA Personal Import corridors, UK MHRA Special Import, EURATOM regulations, and Middle East radiation protection authority guidelines.
• Lead-Shielded Secure Transit: Dispatched in Type A approved radiation containers with dedicated express courier handlers directly to licensed radio-oncology infusion suites worldwide.

Consult our theranostics desk for institutional scheduling, radioligand import requirements, and technical documentation: support@onco-medicine.com or connect via WhatsApp (+91 94275 19809).